Evaluation of nephrotoxic and ototoxic effects of tobramycin in worldwide study.
Tobramycin sulphate, a bactericidal aminoglycoside antibiotic, has been evaluated worldwide in 3,506 patients. Drug-related adverse effects were reported by the investigators in 3.9% of the cases, and included reactions in the nervous system (ototoxicity) in 0.6% and in the kidney in 1.5%. Effects of doubtful relationship to tobramycin occurred in 6.6% of the cases. The effects were usually reversible, although infrequently altered renal or eighth-nerve function appeared to persist in some of the patients. There were no deaths or instances of renal shutdown as a result of tobramycin therapy. Therefore, under the clinical conditions in which it was evaluated, tobramycin appeared to be well tolerated. The association of toxicity with various "risk factors" is discussed.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D004427:Ear Diseases / Q000139:chemically induced*; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D007759:Labyrinth Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012306:Risk; D014031:Tobramycin / Q000009:adverse effects*; D014722:Vestibule, Labyrinth
D000900:Anti-Bacterial Agents; D014031:Tobramycin